The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020)
- PMID: 34406452
- DOI: 10.1007/s00213-021-05964-y
The adverse events of ibogaine in humans: an updated systematic review of the literature (2015-2020)
Abstract
Context: Ibogaine is the main alkaloid of the African shrub Tabernanthe iboga. It produces hallucinogenic and psychostimulant effects, but it is currently known for the anti-addictive properties. Despite the potential therapeutic effects, several cases of fatalities and serious adverse events related to ibogaine/noribogaine use can be found in the literature. Most studies consist in case reports or were conducted under non-controlled settings, so causation cannot be clearly established.
Objectives: To update (2015-2020) the literature on the adverse events and fatalities associated with ibogaine/noribogaine administration.
Methods: Systematic review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).
Results: Eighteen studies were included in the final selection. Highly heterogeneous results were found in terms of kind of product used or the known dosages. The adverse events were classified in acute effects (< 24 h), mainly cardiac (the most common was QTc prolongation), gastrointestinal, neurological, and clinical alterations, and long-lasting effects (> 24 h), mainly persistent cardiac alterations, psychiatric, and neurological signs.
Conclusions: There is a high need of phase I clinical trials that can describe the safety of different dosages of ibogaine with standardized products. Further research should perform clinical profiling of vulnerable populations, and design effective screening methods and clinical procedures.
Keywords: Adverse events; Drug interactions; Ibogaine; Noribogaine; Safety.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Similar articles
-
Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies.Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1527-1542. doi: 10.1007/s00406-023-01590-1. Epub 2023 Mar 22. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 36947216 Review.
-
How toxic is ibogaine?Clin Toxicol (Phila). 2016;54(4):297-302. doi: 10.3109/15563650.2016.1138226. Epub 2016 Jan 25. Clin Toxicol (Phila). 2016. PMID: 26807959 Review.
-
A systematic literature review of clinical trials and therapeutic applications of ibogaine.J Subst Abuse Treat. 2022 Jul;138:108717. doi: 10.1016/j.jsat.2021.108717. Epub 2021 Dec 30. J Subst Abuse Treat. 2022. PMID: 35012793
-
Ibogaine/Noribogaine in the Treatment of Substance Use Disorders: A Systematic Review of the Current Literature.Curr Neuropharmacol. 2023;21(11):2178-2194. doi: 10.2174/1570159X21666221017085612. Curr Neuropharmacol. 2023. PMID: 36263479 Free PMC article.
-
Cytochrome P450 and O-methyltransferase catalyze the final steps in the biosynthesis of the anti-addictive alkaloid ibogaine from Tabernanthe iboga.J Biol Chem. 2018 Sep 7;293(36):13821-13833. doi: 10.1074/jbc.RA118.004060. Epub 2018 Jul 20. J Biol Chem. 2018. PMID: 30030374 Free PMC article.
Cited by
-
The pharmacokinetics and pharmacodynamics of ibogaine in opioid use disorder patients.J Psychopharmacol. 2024 May;38(5):481-488. doi: 10.1177/02698811241237873. Epub 2024 Mar 22. J Psychopharmacol. 2024. PMID: 38519421 Free PMC article.
-
Magnesium-ibogaine therapy in veterans with traumatic brain injuries.Nat Med. 2024 Feb;30(2):373-381. doi: 10.1038/s41591-023-02705-w. Epub 2024 Jan 5. Nat Med. 2024. PMID: 38182784 Free PMC article.
-
5-MeO-DMT: An atypical psychedelic with unique pharmacology, phenomenology & risk?Psychopharmacology (Berl). 2023 Dec 11. doi: 10.1007/s00213-023-06517-1. Online ahead of print. Psychopharmacology (Berl). 2023. PMID: 38072874 Review.
-
Identifying setting factors associated with improved ibogaine safety: a systematic review of clinical studies.Eur Arch Psychiatry Clin Neurosci. 2023 Oct;273(7):1527-1542. doi: 10.1007/s00406-023-01590-1. Epub 2023 Mar 22. Eur Arch Psychiatry Clin Neurosci. 2023. PMID: 36947216 Review.
-
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review.J Psychopharmacol. 2022 Oct;36(10):1100-1117. doi: 10.1177/02698811221116926. Epub 2022 Aug 26. J Psychopharmacol. 2022. PMID: 36017784 Free PMC article. Review.
References
-
- Aceto M, Bowman E, Harris L (1990) Dependence studies of new compounds in the rhesus monkey, rat, and mouse. Natl Instit Drug Addict Res Monogr 95:578–631
-
- Alper KR (2001) Ibogaine: a review. Alkaloids Chem Biol 56:1–38. https://doi.org/10.1016/s0099-9598(01)56005-8 - DOI - PubMed
-
- Alper KR, Lotsof HS. (2007) Psychedelic medicine: new evidence for hallucinogenic substances as treatments. Westport (CT): Praeger Perspectives. The use of ibogaine in the treatment of addictions; p. 43–66.
-
- Alper KR, Lotsof HS, Kaplan CD (2008) The ibogaine medical subculture. J Ethnopharmacol 115:9–24. https://doi.org/10.1016/j.jep.2007.08.034 - DOI - PubMed
-
- Alper KR, Stajić M, Gill JR (2012) Fatalities temporally associated with the ingestion of ibogaine. J Forensic Sci 57(2):398–412. https://doi.org/10.1111/j.1556-4029.2011.02008.x - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources